Molecular Diagnosis & Therapy

, Volume 17, Issue 6, pp 331–342 | Cite as

Monitoring Survivin Expression in Cancer: Implications for Prognosis and Therapy

  • Rodrigo Santa Cruz Guindalini
  • Maria Cecília Mathias Machado
  • Bernardo Garicochea
Review Article

Abstract

Survivin, a member of the inhibitor of apoptosis protein family, is one of the most cancer-specific proteins identified to date. Survivin expression is low or undetectable in most adult tissues, but, alternatively, is overexpressed in a large number of tumors. This multifunctional protein is recognized as a key regulator in apoptosis, proliferation and angiogenesis in the tumor environment. Several studies have shown a correlation between survivin upregulation and poor cancer prognosis, and, as expected, its downregulation or inactivation leads to inhibition of tumor growth. Therefore, survivin has attracted increasing attention both as a potential cancer biomarker and as a new target for anticancer therapies. This review summarizes and discusses survivin expression and its potential as a prognostic and diagnostic biomarker in different types of tumors, as well as provides an overview of the current therapeutic challenges of targeting survivin as a treatment strategy.

References

  1. 1.
    Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3(8):917–21.PubMedCrossRefGoogle Scholar
  2. 2.
    Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999;59(24):6097–102.PubMedGoogle Scholar
  3. 3.
    Ouhtit A, Matrougui K, Bengrine A, Koochekpour S, Zerfaoui M, Yousief Z. Survivin is not only a death encounter but also a survival protein for invading tumor cells. Front Biosci. 2007;12:1260–70.PubMedCrossRefGoogle Scholar
  4. 4.
    Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Conway EM, et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene. 2005;24(12):1994–2007.PubMedCrossRefGoogle Scholar
  5. 5.
    Moniri Javadhesari S, Gharechahi J, Hosseinpour Feizi MA, Montazeri V, Halimi M. Transcriptional expression analysis of survivin splice variants reveals differential expression of survivin-3α in breast cancer. Genet Test Mol Biomarkers. 2013;17(4):314–20.Google Scholar
  6. 6.
    Mola G, Vela E, Fernández-Figueras MT, Isamat M, Muñoz-Mármol AM. Exonization of Alu-generated splice variants in the survivin gene of human and non-human primates. J Mol Biol. 2007;366(4):1055–63.PubMedCrossRefGoogle Scholar
  7. 7.
    Noton EA, Colnaghi R, Tate S, Starck C, Carvalho A, Ko Ferrigno P, et al. Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem. 2006;281(2):1286–95.PubMedCrossRefGoogle Scholar
  8. 8.
    Miura K, Fujibuchi W, Unno M. Splice isoforms as therapeutic targets for colorectal cancer. Carcinogenesis. 2012;33(12):2311–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Troeger A, Siepermann M, Escherich G, Meisel R, Willers R, Gudowius S, et al. Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica. 2007;92(8):1043–50.PubMedCrossRefGoogle Scholar
  10. 10.
    Kanwar JR, Kamalapuram SK, Kanwar RK. Survivin signaling in clinical oncology: a multifaceted dragon. Med Res Rev. 2013;33(4):765–89.Google Scholar
  11. 11.
    Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58(23):5315–20.PubMedGoogle Scholar
  12. 12.
    Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 2004;5(11):897–907.PubMedCrossRefGoogle Scholar
  13. 13.
    Ryan BM, O’Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat. Rev. 2009;35(7):553–62.PubMedCrossRefGoogle Scholar
  14. 14.
    Coumar MS, Tsai F-Y, Kanwar JR, Sarvagalla S, Cheung CHA. Treat cancers by targeting survivin: just a dream or future reality? Cancer Treat Rev. 2013.Google Scholar
  15. 15.
    Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396(6711):580–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res. 2003;9(7):2683–92.PubMedGoogle Scholar
  17. 17.
    Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer. 2001;91(11):2026–32.PubMedCrossRefGoogle Scholar
  18. 18.
    Tu SP, Jiang XH, Lin MCM, Cui JT, Yang Y, Lum CT, et al. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res. 2003;63(22):7724–32.PubMedGoogle Scholar
  19. 19.
    Dean EJ, Ranson M, Blackhall F, Holt SV, Dive C. Novel therapeutic targets in lung cancer: inhibitor of apoptosis proteins from laboratory to clinic. Cancer Treat Rev. 2007;33(2):203–12.PubMedCrossRefGoogle Scholar
  20. 20.
    Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58(22):5071–4.PubMedGoogle Scholar
  21. 21.
    Jiang G, Ren B, Xu L, Song S, Zhu C, Ye F. Survivin may enhance DNA double-strand break repair capability by up-regulating Ku70 in human KB cells. Anticancer Res. 2009;29(1):223–8.PubMedGoogle Scholar
  22. 22.
    Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998;58(9):1808–12.PubMedGoogle Scholar
  23. 23.
    Monzó M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J, et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol. 1999;17(7):2100–4.PubMedGoogle Scholar
  24. 24.
    Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer. 2002;86(6):886–92.PubMedCrossRefGoogle Scholar
  25. 25.
    Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res. 2000;6(1):127–34.PubMedGoogle Scholar
  26. 26.
    Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol. 2002;20(4):1063–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Vogel C, Hager C, Bastians H. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Res. 2007;67(1):339–45.PubMedCrossRefGoogle Scholar
  28. 28.
    Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3(1):46–54.PubMedCrossRefGoogle Scholar
  29. 29.
    Kelly RJ, Lopez-Chavez A, Citrin D, Janik JE, Morris JC. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer. 2011;10:35.PubMedCrossRefGoogle Scholar
  30. 30.
    Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen D-T, et al. Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer. 2011;10(3):188–93.PubMedCrossRefGoogle Scholar
  31. 31.
    Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med. 1999;341(6):452–3.PubMedCrossRefGoogle Scholar
  32. 32.
    Als AB, Dyrskjøt L, von der Maase H, Koed K, Mansilla F, Toldbod HE, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res. 2007;13(15 Pt 1):4407–14.PubMedCrossRefGoogle Scholar
  33. 33.
    Atlasi Y, Mowla SJ, Ziaee SA-M. Differential expression of survivin and its splice variants, survivin-DeltaEx3 and survivin-2B, in bladder cancer. Cancer Detect Prev. 2009;32(4):308–13.PubMedCrossRefGoogle Scholar
  34. 34.
    Gonzalez S, Aubert S, Kerdraon O, Haddad O, Fantoni J-C, Biserte J, et al. Prognostic value of combined p53 and survivin in pT1G3 urothelial carcinoma of the bladder. Am J Clin Pathol. 2008;129(2):232–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Kogiku M, Ohsawa I, Matsumoto K, Sugisaki Y, Takahashi H, Teramoto A, et al. Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor. J Clin Neurosci. 2008;15(11):1198–203.PubMedCrossRefGoogle Scholar
  36. 36.
    Shirai K, Suzuki Y, Oka K, Noda S, Katoh H, Suzuki Y, et al. Nuclear survivin expression predicts poorer prognosis in glioblastoma. J Neurooncol. 2009;91(3):353–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Xu C, Yamamoto-Ibusuki M, Yamamoto Y, Yamamoto S, Fujiwara S, Murakami K, et al. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level. Breast Cancer. 2012 [Epub ahead of print].Google Scholar
  38. 38.
    Petrarca CR, Brunetto AT, Duval V, Brondani A, Carvalho GP, Garicochea B. Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage II and stage III breast cancer. Clin Breast Cancer. 2011;11(2):129–34.PubMedCrossRefGoogle Scholar
  39. 39.
    Yamashita S-I, Masuda Y, Kurizaki T, Haga Y, Murayama T, Ikei S, et al. Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res. 2007;27(4C):2803–8.Google Scholar
  40. 40.
    Brennan DJ, Rexhepaj E, O’Brien SL, McSherry E, O’Connor DP, Fagan A, et al. Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin. Cancer Res. 2008;14(9):2681–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP, et al. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis. 2009;24(8):875–84.PubMedCrossRefGoogle Scholar
  42. 42.
    Kim K, Chie EK, Wu H-G, Kim SG, Lee S-H, Kang GH, et al. High survivin expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer. Int J Colorectal Dis. 2011;26(8):1019–23.PubMedCrossRefGoogle Scholar
  43. 43.
    Takasu C, Shimada M, Kurita N, Iwata T, Sato H, Nishioka M, et al. Survivin expression can predict the effect of chemoradiotherapy for advanced lower rectal cancer. Int J Clin Oncol. 2012 [Epub ahead of print].Google Scholar
  44. 44.
    Brunner A, Riss P, Heinze G, Brustmann H. pHH3 and survivin are co-expressed in high-risk endometrial cancer and are prognostic relevant. Br J Cancer. 2012;107(1):84–90.PubMedCrossRefGoogle Scholar
  45. 45.
    Zhu H, Wang Q, Hu C, Zhang W, Quan L, Liu M, et al. High expression of survivin predicts poor prognosis in esophageal squamous cell carcinoma following radiotherapy. Tumour Biol. 2011;32(6):1147–53.PubMedCrossRefGoogle Scholar
  46. 46.
    Meng J-R, Tang H-Z, Zhou K-Z, Shen W-H, Guo H-Y. TFF3 and survivin expressions associate with a lower survival rate in gastric cancer. Clin Exp Med. 2012 [Epub ahead of print].Google Scholar
  47. 47.
    Deng J-Y, Sun D, Liu X-Y, Pan Y, Liang H. STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer. World J Gastroenterol. 2010;16(42):5380–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Preuss SF, Weinell A, Molitor M, Stenner M, Semrau R, Drebber U, et al. Nuclear survivin expression is associated with HPV-independent carcinogenesis and is an indicator of poor prognosis in oropharyngeal cancer. Br J Cancer. 2008;98(3):627–32.PubMedCrossRefGoogle Scholar
  49. 49.
    Semrau R, Duerbaum H, Temming S, Huebbers C, Stenner M, Drebber U, et al. Prognostic impact of human papillomavirus status, survivin, and epidermal growth-factor receptor expression on survival in patients treated with radiochemotherapy for very advanced nonresectable oropharyngeal cancer. Head Neck. 2012 [Epub ahead of print].Google Scholar
  50. 50.
    Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR, et al. Survivin is highly expressed in CD34(+)38(−) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood. 2012;120(1):173–80.PubMedCrossRefGoogle Scholar
  51. 51.
    Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol. 2004;22(9):1682–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Wang M, Liu B-G, Yang Z-Y, Hong X, Chen G-Y. Significance of survivin expression: prognostic value and survival in stage III non-small cell lung cancer. Exp Ther Med. 2012;3(6):983–8.PubMedGoogle Scholar
  53. 53.
    Nakano J, Huang C, Liu D, Masuya D, Yokomise H, Ueno M, et al. The clinical significance of splice variants and subcellular localisation of survivin in non-small cell lung cancers. Br J Cancer. 2008;98(6):1109–17.PubMedCrossRefGoogle Scholar
  54. 54.
    Kren L, Brazdil J, Hermanova M, Goncharuk VN, Kallakury BVS, Kaur P, et al. Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases. Appl Immunohistochem Mol Morphol. 2004;12(1):44–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Dai C-H, Li J, Shi S-B, Yu L-C, Ge L-P, Chen P. Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery. Jpn J Clin Oncol. 2010;40(4):327–35.PubMedCrossRefGoogle Scholar
  56. 56.
    Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer. 2004;100(4):751–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Akhtar M, Gallagher L, Rohan S. Survivin: role in diagnosis, prognosis, and treatment of bladder cancer. Adv Anat Pathol. 2006;13(3):122–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Song J, Su H, Zhou Y-Y, Guo L-L. Prognostic value of survivin expression in breast cancer patients: a meta-analysis. Tumour Biol. 2013;34(4):2053–62.Google Scholar
  59. 59.
    Krieg A, Werner TA, Verde PE, Stoecklein NH, Knoefel WT. Prognostic and clinicopathological significance of survivin in colorectal cancer: a meta-analysis. PLoS ONE. 2013;8(6):e65338.PubMedCrossRefGoogle Scholar
  60. 60.
    Da C-L, Xin Y, Zhao J, Luo X-D. Significance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesions. World J Gastroenterol. 2009;15(32):4055–61.PubMedCrossRefGoogle Scholar
  61. 61.
    Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006;5(5):1087–98.PubMedCrossRefGoogle Scholar
  62. 62.
    Fulda S. Inhibitor of apoptosis proteins in hematological malignancies. Leukemia. 2009;23(3):467–76.PubMedCrossRefGoogle Scholar
  63. 63.
    Tamm I, Richter S, Oltersdorf D, Creutzig U, Harbott J, Scholz F, et al. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res. 2004;10(11):3737–44.PubMedCrossRefGoogle Scholar
  64. 64.
    Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000;96(5):1921–5.PubMedGoogle Scholar
  65. 65.
    Adida C, Recher C, Raffoux E, Daniel MT, Taksin AL, Rousselot P, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol. 2000;111(1):196–203.PubMedCrossRefGoogle Scholar
  66. 66.
    Sugahara K, Uemura A, Harasawa H, Nagai H, Hirakata Y, Tomonaga M, et al. Clinical relevance of survivin as a biomarker in neoplasms, especially in adult T-cell leukemias and acute leukemias. Int J Hematol. 2004;80(1):52–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Tröger A, Siepermann M, Mahotka C, Wethkamp N, Bülle H, Laws H-J, et al. Role of survivin splice variants in pediatric acute precursor B lymphoblastic leukemia. Klin Padiatr. 2007;219(3):127–33.PubMedCrossRefGoogle Scholar
  68. 68.
    Huang L-N, Wang D-S, Chen Y-Q, Zhao C-L, Gong B-L, Jiang A-B, et al. Expression of survivin and patients survival in non-small cell lung cancer: a meta-analysis of the published studies. Mol Biol Rep. 2013;40(2):917–24.PubMedCrossRefGoogle Scholar
  69. 69.
    Ku JH, Godoy G, Amiel GE, Lerner SP. Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review. BJU Int. 2012;110(5):630–6.PubMedCrossRefGoogle Scholar
  70. 70.
    Wu Y-K, Chen K-T, Kuo Y-B, Huang Y-S, Chan E-C. Quantitative detection of survivin in malignant pleural effusion for the diagnosis and prognosis of lung cancer. Cancer Lett. 2009;273(2):331–5.PubMedCrossRefGoogle Scholar
  71. 71.
    Li J, Chen P, Li X-Q, Bao Q-L, Dai C-H, Ge L-P. Elevated levels of survivin and livin mRNA in bronchial aspirates as markers to support the diagnosis of lung cancer. Int J Cancer. 2013;132(5):1098–104.PubMedCrossRefGoogle Scholar
  72. 72.
    Van der Pol E, Böing AN, Harrison P, Sturk A, Nieuwland R. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev. 2012;64(3):676–705.PubMedCrossRefGoogle Scholar
  73. 73.
    Khan S, Jutzy JMS, Valenzuela MMA, Turay D, Aspe JR, Ashok A, et al. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS ONE. 2012;7(10):e46737.PubMedCrossRefGoogle Scholar
  74. 74.
    Yie S-M, Luo B, Ye N-Y, Xie K, Ye S-R. Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA. Clin Exp Metastasis. 2006;23(5–6):279–89.PubMedCrossRefGoogle Scholar
  75. 75.
    Yie S, Lou B, Ye S, Cao M, He X, Li P, et al. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse. Ann Surg Oncol. 2008;15(11):3073–82.PubMedCrossRefGoogle Scholar
  76. 76.
    Cao M, Yie S-M, Wu S-M, Chen S, Lou B, He X, et al. Detection of survivin-expressing circulating cancer cells in the peripheral blood of patients with esophageal squamous cell carcinoma and its clinical significance. Clin Exp Metastasis. 2009;26(7):751–8.PubMedCrossRefGoogle Scholar
  77. 77.
    Yie S, Lou B, Ye S, He X, Cao M, Xie K, et al. Clinical significance of detecting survivin-expressing circulating cancer cells in patients with non-small cell lung cancer. Lung Cancer. 2009;63(2):284–90.PubMedCrossRefGoogle Scholar
  78. 78.
    Church DN, Talbot DC. Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep. 2012;14(2):120–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Lu J, Tan M, Huang W-C, Li P, Guo H, Tseng L-M, et al. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res. 2009;15(4):1326–34.PubMedCrossRefGoogle Scholar
  80. 80.
    Zhang M, Latham DE, Delaney MA, Chakravarti A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene. 2005;24(15):2474–82.PubMedCrossRefGoogle Scholar
  81. 81.
    Belyanskaya LL, Hopkins-Donaldson S, Kurtz S, Simões-Wüst AP, Yousefi S, Simon H-U, et al. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer. 2005;117(5):755–63.PubMedCrossRefGoogle Scholar
  82. 82.
    Wall NR, O’Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res. 2003;63(1):230–5.PubMedGoogle Scholar
  83. 83.
    Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, et al. Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res. 2000;91(11):1204–9.PubMedCrossRefGoogle Scholar
  84. 84.
    Kappler M, Kotzsch M, Bartel F, Füssel S, Lautenschläger C, Schmidt U, et al. Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clin Cancer Res. 2003;9(3):1098–104.PubMedGoogle Scholar
  85. 85.
    Hayashi N, Asano K, Suzuki H, Yamamoto T, Tanigawa N, Egawa S, et al. Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo. Prostate. 2005;65(1):10–9.PubMedCrossRefGoogle Scholar
  86. 86.
    Vivas-Mejia PE, Rodriguez-Aguayo C, Han H-D, Shahzad MMK, Valiyeva F, Shibayama M, et al. Silencing survivin splice variant 2B leads to antitumor activity in taxane-resistant ovarian cancer. Clin Cancer Res. 2011;17(11):3716–26.PubMedCrossRefGoogle Scholar
  87. 87.
    Nakahara T, Yamanaka K, Hatakeyama S, Kita A, Takeuchi M, Kinoyama I, et al. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer Drugs. 2011;22(5):454–62.PubMedCrossRefGoogle Scholar
  88. 88.
    Yamanaka K, Nakahara T, Yamauchi T, Kita A, Takeuchi M, Kiyonaga F, et al. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin Cancer Res. 2011;17(16):5423–31.PubMedCrossRefGoogle Scholar
  89. 89.
    Carrasco RA, Stamm NB, Marcusson E, Sandusky G, Iversen P, Patel BKR. Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther. 2011;10(2):221–32.PubMedCrossRefGoogle Scholar
  90. 90.
    Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat. 2002;5(2):65–72.PubMedCrossRefGoogle Scholar
  91. 91.
    Dash P, Lotan I, Knapp M, Kandel ER, Goelet P. Selective elimination of mRNAs in vivo: complementary oligodeoxynucleotides promote RNA degradation by an RNase H-like activity. Proc Natl Acad Sci USA. 1987;84(22):7896–900.PubMedCrossRefGoogle Scholar
  92. 92.
    Talbot DC, Ranson M, Davies J, Lahn M, Callies S, André V, et al. Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin Cancer Res. 2010;16(24):6150–8.PubMedCrossRefGoogle Scholar
  93. 93.
    Tanioka M, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y, et al. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011;68(2):505–11.PubMedCrossRefGoogle Scholar
  94. 94.
    Erba HP, Sayar H, Juckett M, Lahn M, Andre V, Callies S, et al. Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Invest New Drugs. 2013;31(4):1023–34.Google Scholar
  95. 95.
    Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, et al. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci. 2011;102(3):614–21.PubMedCrossRefGoogle Scholar
  96. 96.
    Iwasa T, Okamoto I, Takezawa K, Yamanaka K, Nakahara T, Kita A, et al. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br J Cancer. 2010;103(1):36–42.PubMedCrossRefGoogle Scholar
  97. 97.
    Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007;67(17):8014–21.PubMedCrossRefGoogle Scholar
  98. 98.
    Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol. 2008;26(32):5198–203.PubMedCrossRefGoogle Scholar
  99. 99.
    Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y, et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res. 2009;15(11):3872–80.PubMedCrossRefGoogle Scholar
  100. 100.
    Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, Keating AT, et al. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer. 2012;118(12):3128–34.PubMedCrossRefGoogle Scholar
  101. 101.
    Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, et al. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol. 2009;27(27):4481–6.PubMedCrossRefGoogle Scholar
  102. 102.
    Lewis KD, Samlowski W, Ward J, Catlett J, Cranmer L, Kirkwood J, et al. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs. 2011;29(1):161–6.PubMedCrossRefGoogle Scholar
  103. 103.
    Holmes D. Cancer drug’s survivin suppression called into question. Nat Med. 2012;18(6):842–3.PubMedCrossRefGoogle Scholar
  104. 104.
    Arora R, Shuda M, Guastafierro A, Feng H, Toptan T, Tolstov Y, et al. Survivin is a therapeutic target in Merkel cell carcinoma. Sci Transl Med. 2012;4(133):133ra56.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Rodrigo Santa Cruz Guindalini
    • 1
  • Maria Cecília Mathias Machado
    • 2
  • Bernardo Garicochea
    • 3
  1. 1.Instituto do Câncer do Estado de São PauloFaculdade de Medicina da Universidade de São PauloSão PauloBrazil
  2. 2.Escola Bahiana de Medicina e Saúde PúblicaBahiaBrazil
  3. 3.Centro de Oncologia e Instituto de Pesquisa e Ensino, Hospital Sírio LibanêsSão PauloBrazil

Personalised recommendations